| William J Smolinski, DO | |
|
1249 S Cedar Crest Blvd, Suite 100, Allentown, PA 18103-6259 | |
| (610) 770-2200 | |
| (610) 433-7622 |
| Full Name | William J Smolinski |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 37 Years |
| Location | 1249 S Cedar Crest Blvd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861402117 | NPI | - | NPPES |
| 0014941200007 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | OS006757E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Heart Care Group Pc | 8325947062 | 5 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
In Ethiopia, health clinics for teenagers once supported by U.S. foreign aid closed down. In Kenya, a decades-long effort to integrate HIV testing and family planning unraveled.
Researchers from The Miriam Hospital have found that patients who have completed cardiac rehabilitation and who receive telephone counseling that supports exercise are more likely to adhere to an exercise program. Results of the study, funded by the National Heart, Lung and Blood Institute, are published in the American Journal of Preventive Medicine.
Microbes collected from Northern California and throughout the nation will soon blast into orbit for research and a microgravity growth competition on the International Space Station (ISS).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
| Entity Name | The Heart Care Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700967916 PECOS PAC ID: 8325947062 Enrollment ID: O20040102000108 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
In Ethiopia, health clinics for teenagers once supported by U.S. foreign aid closed down. In Kenya, a decades-long effort to integrate HIV testing and family planning unraveled.
Researchers from The Miriam Hospital have found that patients who have completed cardiac rehabilitation and who receive telephone counseling that supports exercise are more likely to adhere to an exercise program. Results of the study, funded by the National Heart, Lung and Blood Institute, are published in the American Journal of Preventive Medicine.
Microbes collected from Northern California and throughout the nation will soon blast into orbit for research and a microgravity growth competition on the International Space Station (ISS).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William J Smolinski, DO 1249 S Cedar Crest Blvd, Suite 100, Allentown, PA 18103-6259 Ph: (610) 770-2200 | William J Smolinski, DO 1249 S Cedar Crest Blvd, Suite 100, Allentown, PA 18103-6259 Ph: (610) 770-2200 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
In Ethiopia, health clinics for teenagers once supported by U.S. foreign aid closed down. In Kenya, a decades-long effort to integrate HIV testing and family planning unraveled.
Researchers from The Miriam Hospital have found that patients who have completed cardiac rehabilitation and who receive telephone counseling that supports exercise are more likely to adhere to an exercise program. Results of the study, funded by the National Heart, Lung and Blood Institute, are published in the American Journal of Preventive Medicine.
Microbes collected from Northern California and throughout the nation will soon blast into orbit for research and a microgravity growth competition on the International Space Station (ISS).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
Jessica Mary Boehmler, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 205, Allentown, PA 18103 Phone: 610-439-8856 Fax: 610-439-8856 | |
Muhammad Majeed, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-5369 | |
Allison Jane Baragona, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1501 N Cedar Crest Blvd Ste 110, Allentown, PA 18104 Phone: 610-821-2828 Fax: 610-821-7915 | |
James A Burke, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 300, Allentown, PA 18103 Phone: 610-402-3110 Fax: 610-402-3112 | |
Stephen R Shore, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1901 Hamilton St Ste 300, Allentown, PA 18104 Phone: 610-628-7900 Fax: 833-816-7513 | |
Tarika Sejal Chowdhary, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 17th & Chew, Suite 101, Allentown, PA 18105 Phone: 610-969-4370 | |
Ashley Vojtek, DO Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 484-862-3200 |